• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Email & Password

Not a member? .

Emervel ®

In 2016, the range, also from Galderma was integrated into their range to create one large range of acid fillers. This meant that EMERVEL ceased as a brand name and all were . Please refer to the page for further .

EMERVEL® is a range of five acid based dermal fillers from Q-Med, a Division of Galderma, the UK distributor of the Toxin brand  and the dermal filler brand . It was introduced to the UK and Europe in 2011.

Emervel dermal fillers are indicated for the of facial lines, for facial contouring and the correction of volume loss, as well as lip .

They are also available with the addition of local anaesthetic lidocaine for added comfort during injection.

cross-linked hyaluronic acid.

The main of Emervel is acid. This is a naturally occurring found in all living . The acid is mixed with a called Diglycidyl Ether (BDDE) to form a gel, which is then purified through to remove trace amounts of BDDE left over from the process.

The hyaluronic acid in Emervel is produced by a biotechnological process from without using any animal products.

Emervel from what the manufacturers call its Optimal Balance Technology™.

Their production method is designed to alter the of the hyaluronic acid gel via a of factors, the levels of cross-linking (a which is needed to ensure the hyaluronic acid is long lasting), the sizes, which are varied to product the differing within the range which aim to have a maximum effect in the layers of the skin into which they are .

Emervel has 4 levels of cross-linking, in 4 levels of gel across the range. A lower level of cross-linking will result in a softer gel suitable for superficial and a higher level of cross-linking results in a firmer gel more resistant to for deeper injection. Within the range, Touch, and Lips share the same smaller particle size with Deep and Volume using increasingly larger sizes for deeper skin application. Particle size or is achieved during the manufacturing process after cross-linking, by sieving the gels through different sizes of mesh.

The actual of the acid is the same throughout the range at 20mg/ml.

Some acid based require what’s called free or hyaluronic acid within the product in order to modify the gel (thickness) and aid in the extrusion or out of the product through the and needle. However, free acid is simply a liquid and has no because it is metabolised by the body quickly upon injection. Also by having a good affinity for water molecules, much like a sponge, the addition of it can result in increased swelling in the area upon injection. The manufacturers note that the viscoelastic of are produced by the cross-linking and particle sizes, as above and not the concentration of acid and thus no free acid is incorporated which they claim makes swelling (oedema) on injection minimal.

No.

Hyaluronic acid is completely broken down within the skin over a period of months, eventually no trace of the filler.

device

members of the medical profession only

There are 5 different for Emervel available which include:

Touch

Touch is a soft and subtle for the of superficial wrinkles, such as peri-oral lines (around the mouth) and peri-orbital lines (around the eyes, crow’s feet). It is injected into the superficial dermis and is available in a prefilled 1 x 1ml syringe and comes complete with 2 x 30G ½ `Ultra Thin Wall` . It is not available with the addition of lidocaine.

Classic

Emervel provides a medium lifting effect and is ideal for moderate lines and wrinkles, such as the naso-labial folds ( lines). The addition of 0.3% ensures during treatment. It is injected into the dermis and is available in a 1 x 1 ml syringe and comes complete with 2 x 30G ½ `Ultra Thin Wall` .

Emervel Lips

Lips is specifically formulated to enhance, define or the lip body and border. The addition of 0.3% lidocaine ensures during treatment. It is injected into the body of the lip and the border and is available in a prefilled 1 x 1 ml syringe and comes complete with 2 x 30G ½ `Ultra Thin Wall` needles.

Deep

Deep has a high volume lifting effect and integrates with the skin matrix to smooth away deep wrinkles or folds such as naso-labial and lines (mouth-to-chin lines). The addition of 0.3% ensures comfort during . It is injected into the deep dermis or upper subcutaneous layer and is available in a prefilled 1 x 1 ml syringe and comes complete with 2 x 27G ½ `Ultra Thin Wall` needles.

Emervel Volume

Emervel Volume also has a very high volume effect and with the skin matrix to lost facial volume associated with ageing. It is suited to patients wishing to enhance or their facial such as the cheekbones, cheeks, chin, or the whole facial oval. The addition of 0.3% lidocaine ensures during . It is into the subcutaneous layer and is available in a prefilled 1 x 2 ml and comes complete with 2 x 23G 1 `Ultra Thin Wall` needles.

Treatment is not for women who are pregnant or breastfeeding.

Emervel dermal fillers are contraindicated in presenting with severe allergies, particularly those with a known or to acid, as well as autoimmune disorder, and to lidocaine or amide (found in formulations).

Treatment with dermal fillers should also be in areas of skin with acute or chronic lesions, or where other fillers, particularly permanent ones have already been .

The Technology™, in the of Emervel, provides a which lasts for months. In trials, some effects have also been seen at 12 months.

Swelling, skin redness (erythema), mild pain, tenderness and are among the common side effects after with dermal such as Emervel. These usually within a few days after .

This on the area(s) treated, the specific product within the range used and how much is required, as well as the practitioner doing the treatment, but price ranges are in the region of £200 - £350 per syringe, with additional used in the same often at a discount.

Emervel has been tested in two multicentre, randomised, evaluator-blinded, European trials. were treated with two different fillers ( vs competitor filler), one on each side of their face.

The first study compared Emervel® Classic with on 52 people in the treatment of facial lines. was found to be as as at 12 and 24 weeks. It was well tolerated, the of people reported none or only mild site reactions and it was associated with significantly less erythema or redness, less oedema or swelling and less pain or tenderness than Restylane (based on patient diary worst scores during the first 3 weeks after baseline injection).

The second study compared Deep with Perlane® on 68 people in the of severe facial lines. Deep was found to offer significantly better efficacy than Perlane at all visits from week 12 to week 48. The of reactions with Emervel Deep were mild and without additional treatment.

 The Emervel French survey: a prospective study of 1,822 patients treated for facial with a new hyaluronic acid filler.

Farhi D, P, Kestemont P, Boineau D, H, Bodokh I, Brun P, Ascher B, Savary J; French Survey Group. Dermatology Clinic, Paris, France.

J Drugs Dermatol. 2013 May;12(5):e88-93.

rejuvenation using a range of acid fillers: efficacy, safety, and over 6 months.

Rzany B, Cartier H, P, Trevidic P, Sattler G, Kerrouche N, Dhuin JC, Ma YM.

Surg. 2012 Jul;38(7 Pt 2): .

Emervel®: full-face rejuvenation with a range of customized hyaluronic acid .

Rzany B.

J Drugs . 2012 Jan;11(1 Suppl):s4.

A complete range of hyaluronic acid filler with physical properties specifically designed for optimal tissue .

Segura S, Anthonioz L, Fuchez F, Herbage B. Galderma R&D, Sophia Antipolis, France.

J Drugs . 2012 Jan;11(1 Suppl):s5-8.

Sustained efficacy and high satisfaction after cheek enhancement with a new hyaluronic acid dermal filler.


P, H, Trevidic P, Rzany B, Sattler G, Kerrouche N, Dhuin JC. CHU Pasteur, Head and Neck Surgery, Nice, France.

J Drugs . 2012 Jan;11(1 Suppl):s9-16.

with a range of hyaluronic acid fillers: efficacy and safety over six months with a focus on the lips.

H, Trevidic P, Rzany B, Sattler G, P, Kerrouche N, Dhuin JC. Centre Medical Saint Jean, Arras, France.

J Drugs Dermatol. 2012 Jan;11(1 Suppl):s17-26.

Correction of tear and periorbital lines with a range of hyaluronic acid fillers.


Rzany B, Cartier H, Kestermont P, Trevidic P, G, Kerrouche N, Dhuin JC. Division of Based Medicine, Charité-Universitätsmedizin, Berlin, .

J Drugs . 2012 Jan;11(1 Suppl):s27-34.

Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of moderate folds: 6-month interim results of a randomized, evaluator-blinded, comparison study.


Rzany B, Bayerl C, Bodokh I, Boineau D, Dirschka T, C, Sebastian M, Sommer B, Poncet M, M, Podda M. dEBM, Charité-Universitätsmedizin, Berlin, Germany.

J Cosmet Laser Ther. 2011 Jun;13(3):107-12.

and safety of a new acid dermal filler in the of severe lines - 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study.


Ascher B, Bayerl C, Brun P, Kestemont P, Rzany B, Poncet M, Guennoun M, Podda M. de Iéna, 11 Rue Fresnel, Paris, France.


J Cosmet Dermatol. 2011 Jun;10(2):94-8.

Industry

©Copyright Consultingroom.com™ Ltd

All information contained within this site is carefully researched and maintained for accuracy of content. Please note that for prospective purchasers of treatments, information and guidance provided does not substitute an consultation with an practitioner.